A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

Research output: Contribution to journalJournal articleResearchpeer-review

R M Naimi, K B Madsen, C Askov-Hansen, C F Brandt, B Hartmann, Jens Juul Holst, P B Mortensen, P B Jeppesen

Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.
Original languageEnglish
JournalRegulatory Peptides
Volume184
Issue number10
Pages (from-to)47-53
Number of pages7
ISSN0167-0115
DOIs
Publication statusPublished - 10 Jun 2013

ID: 45842300